

Phase 2 clinical study of innovative CD19-targeted CAR-T



ONCOLOGY	Phase 2
Product Type	Autologous CAR-T (chimeric antigen receptor-T) cell therapy
Indication	<ul style="list-style-type: none"> • Diffuse large B-cell lymphoma (not otherwise specified, DLBCL, NOS) • Grade 3B follicular lymphoma (FL3B) • High-grade B-cell lymphoma (HGBCL) • Primary mediastinal large B-cell lymphoma (PMBCL)
Target	CD19
MoA (Mechanism of Action)	<ul style="list-style-type: none"> • A novel h1218 based anti-CD19 CAR-T (AT101) • h1218 binds to a membrane-proximal epitope of CD19 compared to FMC63 • h1218 has fast on and off-rates (fly-kiss) to target binding
Competitiveness	<ul style="list-style-type: none"> • Enhanced CAR-T efficacy: Outstanding long-lasting efficacy, leading to increased OS and PFS • New epitope: Opportunities for r/r NHL patients, even those who do not respond to current CAR-T therapies • Humanized antibody (h1218) based CAR-T: Lower immunogenicity and higher CAR-T cell persistency • Automated and closed manufacturing process: Easy to control and keep quality • Exclusive IP rights
Development Stage	Phase II
Route of Administration	IV infusion